Sign in
Taking people in United StatesNo phase

Tests placental membrane products for hard-to-heal diabetic foot and leg ulcers

Tests placental membrane dressings with standard care in adults with hard-to-heal ulcers.

Key facts

Who runs it
C5 Biomedical
Where
Metairie, United StatesSee the site
Trial code
Registry title
Clinical Trial Assessing Human Placental Membrane Products and Standard of Care Versus Standard of Care in Nonhealing DFUs and VLUs
Status
Recruiting
People taking part
177 people, planned
Started
20 Dec 2024
Expected to end
22 Jan 2027
Type of study
Interventional, 6 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Standard of Care - DFU
  • AM/Single - DFU
  • AM/Double - DFU
  • Standard of Care - VLU
  • AM/Single - VLU
  • AM/Double - VLU
Record updated
27 December 2024

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with a diabetic foot ulcer or a venous leg ulcer that has not healed. It compares placental membrane products plus standard wound care with standard care alone over 12 weeks.

Age
18 years or older
Sex
Women and men can join.
Disease stage
Diabetic foot ulcer: type 1 or 2 diabetes, ulcer of 0.7 to 20.0 cm2 present for 4 to 52 weeks, Wagner grade 1 or 2, at least 50% below the malleolus, no exposed tendon or bone. Venous leg ulcer: 0.7 to 20 cm2, present for 4 to 52 weeks, less than 40% smaller in the last 4 weeks.
Earlier treatment
The ulcer must have had at least 4 weeks of standard of care. The foot ulcer must be offloaded for at least 14 days before enrolment. No hyperbaric oxygen therapy or Cellular, Acellular, Matrix-like Product (CAMP) in the last 30 days.
Biomarker or test result
The leg must have enough blood flow, shown by a vascular test within 3 months, for example ABI between 0.7 and 1.3, TBI of 0.6 or more, TCOM of 40 mmHg or more, or biphasic PVR.

Main reasons for not taking part

  • Infected ulcer, cellulitis, osteomyelitis, or exposed tendon or bone
  • Taking immunosuppressants or chemotherapy, or medicines that may slow wound healing
  • HbA1c of 12% (108 mmol/mol) or higher in the last 3 months
  • Ulcer shrank by more than 20% in the 2 weeks before screening, or by 20% or more during the 2-week screening phase
  • Pregnant or planning pregnancy within 6 months, or end stage kidney disease needing dialysis

The registry criteria, word for word

Show all 58 criteriaShow less

Who can take part

  • At least 18 years of age or older
  • Must have diagnosis of type 1 or 2 Diabetes mellitus
  • At enrollment, subject must have a target ulcer with a minimum surface area of 0.7 cm2 and a maximum surface area of 20.0 cm2 measured post debridement with the imaging device
  • Must have a target ulcer that has been present for a minimum of 4 weeks and maximum of 52 weeks of standard of care, prior to screening visit
  • Target ulcer located on the foot with at least 50% of the ulcer below the malleolus
  • Target ulcer that is Wagner 1 or 2 grade, extending at least through the dermis or subcutaneous tissue and may involve the muscle provided it is below the medial aspect of the malleolus. The ulcer may not include exposed tendon or bone
  • Subject's affected limb must have adequate perfusion confirmed by vascular assessment. Any of the following methods performed within 3 months of the first screening visit are acceptable:; ABI between 0.7 and <= 1.3; TBI >= 0.6; TCOM >= 40 mmHg; PVR: biphasic
  • If subject has two or more ulcers, they must be separated by 2 cm. The largest ulcer satisfying the inclusion and exclusion criteria will be designated as the target ulcer
  • Target ulcer must be located on the plantar aspect of the foot and must be offloaded for at least 14 days prior to enrollment
  • Subject must consent to using the prescribed offloading method for the duration of the study
  • Subject must agree to attend weekly study visits
  • Subject must be willing and able to participate in the consent process
  • Potential subjects are required to meet all the following criteria for enrollment in the study
  • Subjects must be at least 18 years of age or older
  • At randomization subjects must have a target ulcer with a minimum surface area of 0.7 cm2 and a maximum surface area of 20 cm2 measured post-debridement
  • The target ulcer must have been present for a minimum of 4 weeks and a maximum of 52 weeks of standard of care prior to the initial screening visit
  • No visible signs of healing objectively, less than 40% reduction in wound size in the last 4 weeks
  • The affected limb must have adequate perfusion confirmed by vascular assessment. Any of the following methods performed within 3 months of the first screening visit are acceptable:; ABI between 0.7 and ≤ 1.3; TBI ≥ 0.6; TCOM ≥ 40 mmHg; PVR: biphasic
  • If the potential subject has two or more ulcers, they must be separated by at least 2 cm post-debridement. The largest ulcer satisfying the inclusion and exclusion criteria will be designated as the target ulcer
  • The potential subject must agree to attend the weekly study visits required by the protocol
  • The potential subject must be willing and able to participate in the informed consent process

Who cannot take part

  • The subject is receiving immunosuppressants (including systemic corticosteroids at doses greater than 10 mg of prednisone per day or equivalent) or cytotoxic chemotherapy or is taking medications that the PI believes will interfere with wound healing (e.g., biologics)
  • Subject has a previous partial amputation on the affected foot that results in a deformity that impedes proper offloading of the target ulcer
  • The surface area of the subject's target ulcer has reduced in size by more than 20% in the 2 weeks prior to the initial screening visit ("historical" run-in period). Imaging Device is not required for measurements taken during the historical run-in period (e.g., calculating surface area using length X width is acceptable)
  • Subject has participated in a clinical trial involving treatment with an investigational product within the previous 30 days
  • Subject was treated with hyperbaric oxygen therapy or a Cellular, Acellular, Matrix-like Product (CAMP) in the 30 days prior to screening
  • The potential subject is receiving immunosuppressants (including systemic corticosteroids at doses greater than 10 mg of prednisone per day or equivalent) or cytotoxic chemotherapy or is taking medications that the PI believes will interfere with wound healing (e.g., biologics)
  • The surface area of the target ulcer has reduced in size by more than 20% in the 2 weeks prior to the initial screening visit ("historical" run-in period). Imaging Device is not required for measurements taken during the historical run-in period (e.g., calculating surface area using length X width is acceptable)
  • The surface area measurement of the target ulcer decreases by 20% or more during the active 2-week screening phase: the 2 weeks from the initial screening visit (SV-1) to the TV-1 visit during which time the potential subject received SOC
  • Participation in a clinical trial involving treatment with an investigational product within the previous 30 days
  • The potential subject was treated with hyperbaric oxygen therapy (HBOT) or a Cellular, Acellular, Matrix-like Product (CAMP) in the 30 days prior to the initial screening visit
  • Subject's target ulcer is not secondary to diabetes
  • Target ulcer is infected or there is cellulitis in the surrounding skin
  • Target ulcer exposes tendon or bone
  • Evidence of osteomyelitis complicating the target ulcer
  • Infection in the target ulcer or in a remote location that requires systemic antibiotic therapy
  • Subject has applied topical steroids to the ulcer surface within one month of initial screening
  • The surface area measurement of the subject's target ulcer decreases by 20% or more during the active 2-week screening phase
  • Subject has acute Charcot foot, or an inactive Charcot foot, which impedes proper offloading of the target ulcer
  • Subject has end stage renal disease requiring dialysis
  • The subject, in opinion of the Investigator, has a medical or psychological condition that may interfere with study assessments
  • The target ulcer is infected, requires systemic antibiotic therapy, or there is cellulitis in the surrounding skin
  • The target ulcer exposes tendon or bone
  • There is evidence of osteomyelitis complicating the target ulcer
  • The potential subject has applied topical steroids to the ulcer surface within one month of initial screening
  • The potential subject has end stage renal disease requiring dialysis
  • A potential subject who, in the opinion of the investigator, has a medical or psychological condition that may interfere with study assessments
  • A subject has a wound with active or latent infection is excluded
  • A subject with a disorder that would create unacceptable risk of post-operative complications is excluded
  • Subject has a glycated hemoglobin (HbA1c) greater than or equal to 12% within 3 months of the initial screening visit
  • The potential subject has glycated hemoglobin (HbA1c) greater than or equal to 12% within 3 months of the initial screening visit
  • Subject is known to have a life expectancy of < 6 months
  • Subject is taking hydroxyurea
  • Subject is a woman who is pregnant or considering becoming pregnant in the next 6 months
  • Subject has a malnutrition indicator score <17 as measured on the Mini Nutritional Assessment
  • The potential subject is known to have a life expectancy of < 6 months
  • Women who are pregnant or considering becoming pregnant within the next 6 months
  • The subject has a malnutrition indicator score <17 as measured on the Mini Nutritional Assessment

Where in United States

  • Poirot PodiatryMetairie, United StatesContact: Donna BeletteTaking people

About the trial

What the trial wants to find out

The purpose of the study is to evaluate the efficacy of multiple human placental membrane products and Standard of Care (SOC) versus SOC alone in the management of nonhealing diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs) over 12 weeks using a modified platform trial design.

The 6 groups in the trial

  • Standard of Care - DFUExisting treatment, for comparison

    Debridement, reduction of bacterial burden, and proper moisture balance using dressings. Off-loading using the off-loading boot or total contact cast (TCC).

  • AM/Single - DFUTreatment being tested

    AM/Single is an air-dried, sterile single layer human amniotic membrane allograft.

  • AM/Double - DFUTreatment being tested

    AM/Double is an air-dried, sterile double layer human amniotic membrane allograft.

  • Standard of Care - VLUExisting treatment, for comparison

    Debridement, reduction of bacterial burden, and proper moisture balance using dressings. Compression using multilayer compression wraps.

  • AM/Single - VLUTreatment being tested

    AM/Single is an air-dried, sterile single layer human amniotic membrane allograft.

  • AM/Double - VLUTreatment being tested

    AM/Double is an air-dried, sterile double layer human amniotic membrane allograft.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Multicenter, Prospective, Randomized Controlled Modified Platform Trial Assessing the Efficacy of Human Placental Membrane Products and Standard of Care Versus Standard of Care Alone in the Management of Nonhealing Diabetic Foot Ulcers and Venous Leg Ulcers.
Plain-language title
Tests placental membrane products for hard-to-heal diabetic foot and leg ulcersGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
27 December 2024